Prasad D. Trivedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prasad D. Trivedi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Barry J. Byrne
University of Florida
3 shared publications Chenghui Yu
Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA
2 shared publications- Evan J. Johnson
Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA
2 shared publications - Nathalie Clément
Pediatrics, University of Florida, Gainesville, FL
2 shared publications Payel Chaudhuri
Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA
2 shared publicationsTina Caton
Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA
2 shared publications
Latest Publications
- Open Access
Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines
Efficient and targeted delivery of a DNA payload is vital for developing safe gene therapy. Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. Adenovirus vectors can be used in gene therapy by altering the wild-type virus and making it replication-defective; specific viral genes can be removed and replaced with a segment that holds a therapeutic gene, and this vector can be used as delivery vehicle for tissue specific gene delivery. Modified conditionally replicative–oncolytic adenoviruses target tumors exclusively and have been studied in clinical trials extensively. This comprehensive review seeks to offer a summary of adenovirus vectors, exploring their characteristics, genetic enhancements, and diverse applications in clinical and preclinical settings. A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine clinical trials for various diseases. Additionally, we tackle current challenges and future avenues for optimizing adenovirus vectors, promising to open new frontiers in the fields of cell and gene therapies.
Open AccessEvolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines
Efficient and targeted delivery of a DNA payload is vital for developing safe gene therapy. Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. Adenovirus vectors can be used in gene therapy by altering the wild-type virus and making it replication-defective; specific viral genes can be removed and replaced with a segment that holds a therapeutic gene, and this vector can be used as delivery vehicle for tissue specific gene delivery. Modified conditionally replicative–oncolytic adenoviruses target tumors exclusively and have been studied in clinical trials extensively. This comprehensive review seeks to offer a summary of adenovirus vectors, exploring their characteristics, genetic enhancements, and diverse applications in clinical and preclinical settings. A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine clinical trials for various diseases. Additionally, we tackle current challenges and future avenues for optimizing adenovirus vectors, promising to open new frontiers in the fields of cell and gene therapies.
- Open Access
- 25 December 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 24, 154-170
Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
- 25 December 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 24, 154-170
Open AccessComparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
- Open Access
- 1 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 1-13
NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform
- 1 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 1-13
Open AccessNaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform